G
Giuseppe Patti
Researcher at University of Eastern Piedmont
Publications - 346
Citations - 12093
Giuseppe Patti is an academic researcher from University of Eastern Piedmont. The author has contributed to research in topics: Medicine & Percutaneous coronary intervention. The author has an hindex of 47, co-authored 268 publications receiving 10107 citations. Previous affiliations of Giuseppe Patti include Catholic University of the Sacred Heart & The Catholic University of America.
Papers
More filters
Journal ArticleDOI
Reduced Rate of Hospital Admissions for ACS during Covid-19 Outbreak in Northern Italy.
Ovidio De Filippo,Fabrizio D'Ascenzo,Filippo Angelini,Pier Paolo Bocchino,Federico Conrotto,Andrea Saglietto,Gioel Gabrio Secco,Gianluca Campo,Guglielmo Gallone,Roberto Verardi,Luca Gaido,Mario Iannaccone,Marcello Galvani,Fabrizio Ugo,Umberto Barbero,Vincenzo Infantino,Luca Olivotti,Marco G. Mennuni,Sebastiano Gili,Fabio Infusino,Matteo Vercellino,Ottavio Zucchetti,Gianni Casella,Massimo Giammaria,Giacomo Boccuzzi,Paolo Tolomeo,Baldassarre Doronzo,Gaetano Senatore,Walter Grosso Marra,Andrea Rognoni,Daniela Trabattoni,Luca Franchin,Andrea Borin,Francesco Bruno,Alessandro Galluzzo,Alfonso Gambino,Annamaria Nicolino,Alessandra Truffa Giachet,Gennaro Sardella,Francesco Fedele,Silvia Monticone,Antonio Montefusco,Pierluigi Omedè,Mauro Pennone,Giuseppe Patti,Massimo Mancone,Gaetano M. De Ferrari +46 more
TL;DR: During the Covid-19 outbreak in northern Italy, the daily rate of admissions for acute coronary syndrome at 15 hospitals was significantly lower than in previous outbreaks.
Journal ArticleDOI
Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study
Giuseppe Patti,Giuseppe Colonna,Vincenzo Pasceri,Leonardo Lassandro Pepe,Antonio Montinaro,Germano Di Sciascio +5 more
TL;DR: Pretreatment with a 600-mg loading dose of clopidogrel 4 to 8 hours before the procedure is safe and, as compared with the conventional 300-mg dose, significantly reduced periprocedural MI in patients undergoing percutaneous coronary intervention.
Journal ArticleDOI
Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study
Giuseppe Patti,Massimo Chello,Dario Candura,Vincenzo Pasceri,Andrea D'Ambrosio,Elvio Covino,Germano Di Sciascio +6 more
TL;DR: Treatment with atorvastatin 40 mg/d, initiated 7 days before surgery, significantly reduces the incidence of postoperative AF after elective cardiac surgery with cardiopulmonary bypass and shortens hospital stay.
Journal ArticleDOI
Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study
Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio +5 more
TL;DR: Pretreatment with atorvastatin 40 mg/d for 7 days significantly reduces procedural myocardial injury in elective coronary intervention and may influence practice patterns with regard to adjuvant pharmacological therapy before percutaneous revascularization.
Journal ArticleDOI
Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial.
Giuseppe Patti,Vincenzo Pasceri,Giuseppe Colonna,Marco Miglionico,Dionigi Fischetti,Gennaro Sardella,Antonio Montinaro,Germano Di Sciascio +7 more
TL;DR: The ARMYDA-ACS trial indicates that even short-term pretreatment with atorvastatin may improve outcomes in patients with ACS undergoing early invasive strategy, and may support routine use of high-dose statins before intervention in Patients with ACS.